Biological monoclonal antibodies such as infliximab have significantly remodeled inflammatory bowel disease's treatment course. Despite multiple side effects reported with infliximab, this medication has shown to be robust and practical. There is a paucity of cases reporting venous thromboembolism (VTE) occurrence during the treatment with infliximab. Although such an association's exact mechanism is still not precise, we should be aware of the drug thromboembolic aptitude. Close attention should be given to patients who started infliximab infusion for any symptoms of pulmonary embolism or deep vein thrombosis.